J&J's depression drug Spravato hits $1B in 2024 sales, up 56% from 2023, with expanded label approval and 140,000+ patients ...

One of Inhibrx Biosciences’ antibody candidates has shown encouraging early efficacy in colorectal cancer. But its safety is ...

Just over 20 years ago, the people of California voted to spend billions of dollars on an exciting new idea to remake ...

Study links GLP-1 diabetes drugs like Novo's Ozempic and Eli Lilly's Mounjaro to 12% lower Alzheimer's risk, ahead of Novo's ...

ArriVent BioPharma, led by Bing Yao, licenses ADC MRG007 from Lepu Biopharma for $47M upfront, adding the drug to a portfolio ...

The Trump administration’s decision to withdraw from the World Health Organization could complicate US access to health ...

A revived legal challenge to the abortion pill mifepristone will be an early test for President Donald Trump’s administration ...

J&J’s Spravato nasal spray received a label expansion on Tuesday, now approved as a standalone treatment for major depressive ...

A new FDA warning letter for French pharmaceutical company Sanofi cited a handful of issues at its biologics factory in ...

UnitedHealth's OptumRx to pass 100% of drug rebates to clients by 2028, but critics say GPO structure may still hide true ...

Stanford University professor Irv Weissman and a colleague published a paper that represented a new way to target some ...

Ascentage Pharma seeks $133M via US listing, markets olverembatinib in China with Takeda holding global rights. CEO Dajun ...